Literature DB >> 7602098

Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies.

H Lindhofer1, R Mocikat, B Steipe, S Thierfelder.   

Abstract

Conventional mouse/mouse or rat/rat hybrid-hybridoma supernatants contain up to 10 different IgG molecules consisting of various combinations of heavy and light chains. Hence, the yield of functional bispecific Ab is low, and purification is often complicated, hampering a general preclinical evaluation of, e.g., bispecific Ab-mediated tumor immunotherapy in animal models. In experiments to overcome this drawback we found that fusion of rat with mouse hybridomas opens the possibility of large scale production of bispecific Ab due to the increased incidence of correctly paired Ab and facilitated purification. In essence, rat/mouse quadroma-derived bispecific Ab have the following advantages: 1) enrichment of functional bispecific Ab because of preferential species-restricted heavy/light chain pairing (observed in four of four rat-mouse quadromas) in contrast to the random pairing in conventional mouse/mouse or rat/rat quadromas, and 2) a possible one-step purification of the quadroma supernatant with protein A. This simple chromatography step does not bind unwanted variants with parental rat/rat heavy chain configuration, and the desired rat/mouse bispecific Ab are retained, which can then easily be separated from parental mouse Ab by sequential pH elution.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7602098

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  59 in total

Review 1.  Bispecific T-cell engagers for cancer immunotherapy.

Authors:  Amelia M Huehls; Tiffany A Coupet; Charles L Sentman
Journal:  Immunol Cell Biol       Date:  2014-11-04       Impact factor: 5.126

2.  World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA.

Authors:  Eugen Dhimolea; Janice M Reichert
Journal:  MAbs       Date:  2012 Jan-Feb       Impact factor: 5.857

Review 3.  Cancer therapy with bispecific antibodies: Clinical experience.

Authors:  Archana Thakur; Lawrence G Lum
Journal:  Curr Opin Mol Ther       Date:  2010-06

4.  Heavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by UHR-ESI-QTOF mass spectrometry.

Authors:  Wolfgang Schaefer; Hans R Völger; Stefan Lorenz; Sabine Imhof-Jung; Jörg T Regula; Christian Klein; Michael Mølhøj
Journal:  MAbs       Date:  2015-10-23       Impact factor: 5.857

Review 5.  Advances in Antibody Design.

Authors:  Kathryn E Tiller; Peter M Tessier
Journal:  Annu Rev Biomed Eng       Date:  2015-08-14       Impact factor: 9.590

Review 6.  Therapeutic antibodies: successes, limitations and hopes for the future.

Authors:  Patrick Chames; Marc Van Regenmortel; Etienne Weiss; Daniel Baty
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

Review 7.  Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on.

Authors:  Gert Riethmüller
Journal:  Cancer Immun       Date:  2012-05-01

Review 8.  Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

Authors:  Patrick Chames; Daniel Baty
Journal:  MAbs       Date:  2009 Nov-Dec       Impact factor: 5.857

Review 9.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

10.  Controlled conductivity at low pH in Protein L chromatography enables separation of bispecific and other antibody formats by their binding valency.

Authors:  Chen Chen; Tetsuya Wakabayashi; Masaru Muraoka; Feng Shu; Chia Wei Shan; Chong Chor Kun; Ching Tim Jang; Ishin Soehano; Yuichiro Shimizu; Tomoyuki Igawa; Jun-Ichi Nezu
Journal:  MAbs       Date:  2019-03-21       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.